IRCCS Centro Neurolesi "Bonino-Pulejo" Messina, Italy.
J Int Med Res. 2021 Nov;49(11):3000605211055036. doi: 10.1177/03000605211055036.
To compare selective serotonin reuptake inhibitors (SSRIs) and nootropic drugs in the reduction of anxiety and depressive symptoms in post-stroke patients.
This retrospective cohort study included patients diagnosed with post-stroke depression that were treated with either SSRIs or nootropic drugs (i.e. citicoline or choline alphoscerate). Depression and anxiety were assessed using the Hamilton Rating Scales. Statistical associations between the use of nootropic drugs and mood disorder improvements were determined by measuring assessment scores at 6-months.
A total of 44 post-stroke patients with depression (aged 45-75 years) were enrolled in the study: 20 were treated with SSRIs and 24 received nootropic drugs. From baseline to follow-up, the SSRI group showed a large effect size with regard depression (success rate difference [SRD] 0.57; 95% confidence interval [CI] 0.21, 0.79) and anxiety (SRD 0.49; 95% CI 0.14, 0.74), whereas the nootropic group showed a small effect size for depression (SRD 0.16; 95% CI -0.17, 0.46) and a small effect size for anxiety (SRD 0.36; 95% CI -0.03, 0.62).
The administration of nootropic drugs could be a valid therapeutic strategy to manage post-stroke patients suffering from mild-moderate anxiety or anxious-depressive syndrome, but this requires further research.
比较选择性 5-羟色胺再摄取抑制剂（SSRIs）和益智药在降低脑卒中后患者焦虑和抑郁症状中的作用。
本回顾性队列研究纳入了接受 SSRIs 或益智药（即胞磷胆碱或胞二磷胆碱）治疗的脑卒中后抑郁患者。使用汉密尔顿抑郁量表和汉密尔顿焦虑量表评估抑郁和焦虑。通过测量 6 个月时的评估评分，确定使用益智药与情绪障碍改善之间的统计学关联。
共纳入 44 例脑卒中后抑郁患者（年龄 45-75 岁）：20 例接受 SSRIs 治疗，24 例接受益智药治疗。从基线到随访，SSRIs 组的抑郁（成功率差异 [SRD] 0.57；95%置信区间 [CI] 0.21，0.79）和焦虑（SRD 0.49；95% CI 0.14，0.74）的效应量较大，而益智药组的抑郁（SRD 0.16；95% CI -0.17，0.46）和焦虑（SRD 0.36；95% CI -0.03，0.62）的效应量较小。
益智药的应用可能是治疗轻中度焦虑或焦虑抑郁综合征脑卒中后患者的有效治疗策略，但这需要进一步研究。
